Literature DB >> 15755702

[The effects of obstructive sleep apnea hypopnea syndrome on cardiovascular system].

Neşe Dursunoğlu1, Dursun Dursunoğlu.   

Abstract

Obstructive sleep apnea hypopnea syndrome (OSAHS) is characterized by repetitive upper airway obstruction during sleep and it is commonly seen in the adult population, 4% in the men, 2% in the women. The most common nocturnal symptom is snoring while the most common daytime symptom is excessive daytime sleepiness. The gold standard in the diagnosis is polysomnography. Nasal continuous positive airway pressure is the most efficient therapy in the treatment and prevention of the disease. The OSAHS may cause cardiovascular complications in long-term, including systemic hypertension, pulmonary hypertension, congestive heart failure, arrhythmias, stroke and myocardial infarction. All these complications increase the morbidity and mortality of OSAHS. In this paper, effects of OSAHS on cardiovascular system were reviewed.

Entities:  

Mesh:

Year:  2005        PMID: 15755702

Source DB:  PubMed          Journal:  Anadolu Kardiyol Derg        ISSN: 1302-8723


  3 in total

1.  The effect of septoplasty on pulmonary artery pressure and right ventricular function in nasal septum deviation.

Authors:  Gulay Ozkececi; Onder Akci; Abdulkadir Bucak; Sahin Ulu; Zafer Yalım; Abdullah Aycicek; Ersel Onrat; Alaettin Avsar
Journal:  Eur Arch Otorhinolaryngol       Date:  2016-04-13       Impact factor: 2.503

2.  The effect of continuous positive airway pressure treatment on inflammatory parameters and periostin levels in patients with obstructive sleep apnea syndrome.

Authors:  Fatma Tosun; Cenk Babayiğit; Nursel Dikmen; Serdar Doğan; Emre Dirican
Journal:  Sleep Breath       Date:  2022-04-27       Impact factor: 2.816

3.  Effects of CPAP on right ventricular myocardial performance index in obstructive sleep apnea patients without hypertension.

Authors:  Nese Dursunoglu; Dursun Dursunoglu; Sibel Ozkurt; Sükrü Gür; Güllü Ozalp; Fatma Evyapan
Journal:  Respir Res       Date:  2006-02-06
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.